Labcorp Holdings (LH) Earnings Expected to Grow: Should You Buy?

Labcorp Holdings (LH) is poised to report Q2 2025 earnings on July 24, with consensus estimates forecasting EPS of $4.14 (+5.1% YoY) on revenues of $3.49 billion (+8.3% YoY). Despite a slight 0.09% downward revision in consensus EPS over the past 30 days, the company's positive Zacks Earnings ESP of +0.51% combined with a Zacks Rank #3 strongly suggests a high probability of an earnings beat. This outlook, supported by Labcorp's track record of exceeding EPS estimates in the last four quarters, positions the stock for potential positive reaction post-announcement.

Analysis

Labcorp Holdings is approaching its Q2 2025 earnings report with strong indicators of a potential earnings per share (EPS) beat. Consensus estimates project significant year-over-year growth, with revenues expected to rise 8.3% to $3.49 billion and EPS to increase 5.1% to $4.14. Despite a marginal 0.09% downward revision in the consensus EPS over the last 30 days, more recent analyst activity captured by the Zacks Earnings ESP is positive at +0.51%. This, combined with a Zacks Rank of #3 (Hold), creates a scenario that has historically preceded a positive earnings surprise nearly 70% of the time. This outlook is further supported by Labcorp's consistent performance, having surpassed consensus EPS estimates in each of the last four quarters. The company's position appears particularly robust when contrasted with industry peer Icon PLC, which is forecasting year-over-year declines in both revenue (-6.4%) and EPS (-15.2%) and has a negative Earnings ESP of -1.38%, making a beat for them less certain.

Key Decisions for Investors

• Given the positive +0.51% Earnings ESP and a strong history of beating estimates, investors could consider the stock favorably positioned for a short-term catalyst from a potential earnings surprise on July 24.
• Beyond the headline EPS number, focus should be on management's forward-looking guidance and commentary during the earnings call, as this will be critical for determining the sustainability of the projected 8.3% revenue growth and any subsequent stock price momentum.
• The starkly negative outlook for peer Icon PLC highlights Labcorp's relative fundamental strength within the Medical Services sector, suggesting it may be a preferred holding for investors seeking exposure to this industry.